Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | POLD1 | P28340 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.31 |
| ▸ | CHAT | P28329 | 1/20 | 0.31 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662649 | 0.86 | POLB (0.57) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL19662715 | 0.86 | POLB (0.57) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL24913471 | 0.83 | POLB (0.36) | POLA1POLBPOLD1P2RY6CHAT | |
| SCHEMBL21786808 | 0.82 | POLG (0.45) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL19663213 | 0.82 | POLG (0.45) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL21786802 | 0.82 | POLB (0.33) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL21787152 | 0.81 | POLB (0.39) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL21786896 | 0.81 | CHAT (0.46) | POLBCHATNAA50 | |
| SCHEMBL24913427 | 0.81 | POLB (0.32) | POLA1POLBPOLD1 | |
| SCHEMBL24913513 | 0.81 | POLB (0.32) | POLA1POLBPOLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | POLA1 142/4885POLB 11/4885POLD1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.